Checkpoint Therapeutics (NASDAQ:CKPT – Get Free Report) issued its quarterly earnings data on Tuesday. The company reported ($0.23) EPS for the quarter, missing analysts’ consensus estimates of ($0.15) by ($0.08), Zacks reports.
Checkpoint Therapeutics Stock Up 4.4 %
Shares of CKPT opened at $3.78 on Friday. Checkpoint Therapeutics has a twelve month low of $1.36 and a twelve month high of $3.97. The stock’s fifty day simple moving average is $2.79 and its 200 day simple moving average is $2.33.
Analyst Ratings Changes
Separately, HC Wainwright reiterated a “buy” rating and set a $20.00 price objective on shares of Checkpoint Therapeutics in a research report on Thursday.
Checkpoint Therapeutics Company Profile
Checkpoint Therapeutics, Inc, a clinical-stage immunotherapy and targeted oncology company, focuses on the acquisition, development, and commercialization of novel treatments for patients with solid tumor cancers in the United States and internationally. The company's lead antibody product candidate is Cosibelimab, which is in Phase 1 clinical trial to treat patients with selected recurrent or metastatic cancers; and CK-302, a product candidate in preclinical trials for hematological malignancies and solid tumors.
See Also
- Five stocks we like better than Checkpoint Therapeutics
- What is the Australian Securities Exchange (ASX)
- Top-Performing Non-Leveraged ETFs This Year
- How to Know Which Cryptocurrency to Buy: A Guide for Investors
- Rivian’s Wild Ride: Is the Dip a Buying Opportunity?
- Business Services Stocks Investing
- Freshworks Stock Soars 50% – Is This the Perfect Entry Point?
Receive News & Ratings for Checkpoint Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Checkpoint Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
